RxDoctor Payments Data

Henry Ssentongo, MD

Hospitalist · Grants Pass, ORNPI 1639418353

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Boston Scientific at 28.4% of the total. Among hospitalist clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$332in general payments, 2019–2025

Across 8 payments — averaging $41.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$94
  • AbbVie$90
  • Fisher & Paykel Healthcare Inc$34
  • Vifor Pharma, Inc.$32
  • Novartis$25
  • Merck$22
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$332100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$332 in reported general payments places this provider in the 90th percentile of 395 hospitalist providers in Oregon.

See all hospitalist providers in Oregon

Medicare billing

Part B allowed, 2024
$163,592
Medicare patients
473
Services billed
1,414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$31,535
FarxigaDapagliflozin Propanediol27$16,215
EntrestoSacubitril/Valsartan16$9,348
Metoprolol Succinate54$795
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen106$765
Albuterol Sulfate HfaAlbuterol Sulfate24$642
Pantoprazole Sodium89$564
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav72$541
Linezolid16$523
Cefdinir49$508
Bumetanide31$496
Rosuvastatin Calcium32$432
ClopidogrelClopidogrel Bisulfate37$267
Carvedilol47$263
Levetiracetam11$254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$25$9,34816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 395 hospitalist providers in Oregon.

Other hospitalist in Grants Pass

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →